Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 192

1.

Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective.

Heading R, Bardhan K, Hollerbach S, Lanas A, Fisher G.

Aliment Pharmacol Ther. 2006 Jul 15;24(2):207-36. Review.

PMID:
16842449
[PubMed - indexed for MEDLINE]
Free Article
2.

Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective.

Tack J, Fried M, Houghton LA, Spicak J, Fisher G.

Aliment Pharmacol Ther. 2006 Jul 15;24(2):183-205. Review.

PMID:
16842448
[PubMed - indexed for MEDLINE]
Free Article
3.

Safety and tolerability of tegaserod in irritable bowel syndrome management.

Berardi RR.

J Am Pharm Assoc (2003). 2004 Jan-Feb;44(1):41-51. Review.

PMID:
14965152
[PubMed - indexed for MEDLINE]
4.

Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.

Hasler WL, Schoenfeld P.

Drug Saf. 2004;27(9):619-31. Review.

PMID:
15230644
[PubMed - indexed for MEDLINE]
5.

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.

Rahimi R, Nikfar S, Abdollahi M.

Clin Ther. 2008 May;30(5):884-901. doi: 10.1016/j.clinthera.2008.05.002.

PMID:
18555935
[PubMed - indexed for MEDLINE]
6.

Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.

Fock KM, Wagner A; Asia Pacific Gastroenterology Group.

J Gastroenterol Hepatol. 2007 Aug;22(8):1190-8. Epub 2007 May 24.

PMID:
17524039
[PubMed - indexed for MEDLINE]
7.

Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review.

Rivkin A.

Clin Ther. 2003 Jul;25(7):1952-74. Review.

PMID:
12946544
[PubMed - indexed for MEDLINE]
8.

The spectrum of irritable bowel syndrome: A clinical review.

Gilkin RJ Jr.

Clin Ther. 2005 Nov;27(11):1696-709. Review.

PMID:
16368443
[PubMed - indexed for MEDLINE]
9.

Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.

Chang L, Chey WD, Harris L, Olden K, Surawicz C, Schoenfeld P.

Am J Gastroenterol. 2006 May;101(5):1069-79. Review.

PMID:
16606352
[PubMed - indexed for MEDLINE]
10.

Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.

Chey WD, Cash BD.

Expert Opin Investig Drugs. 2005 Feb;14(2):185-93. Review.

PMID:
15757394
[PubMed - indexed for MEDLINE]
11.

Rationale for using serotonergic agents to treat irritable bowel syndrome.

Baker DE.

Am J Health Syst Pharm. 2005 Apr 1;62(7):700-11; quiz 712-3. Review.

PMID:
15790796
[PubMed - indexed for MEDLINE]
12.

Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.

Chey WD, Paré P, Viegas A, Ligozio G, Shetzline MA.

Am J Gastroenterol. 2008 May;103(5):1217-25. doi: 10.1111/j.1572-0241.2008.01808.x.

PMID:
18477346
[PubMed - indexed for MEDLINE]
13.

The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review.

Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS.

Am J Gastroenterol. 2009 Apr;104(4):1033-49; quiz 1050. doi: 10.1038/ajg.2009.25. Epub 2009 Mar 10. Review.

PMID:
19277023
[PubMed - indexed for MEDLINE]
14.

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG.

Am J Gastroenterol. 2007 Aug;102(8):1709-19. Epub 2007 May 17.

PMID:
17509028
[PubMed - indexed for MEDLINE]
15.

The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.

Lewis JH.

Drug Saf. 2011 Jul 1;34(7):545-65. doi: 10.2165/11590690-000000000-00000. Review.

PMID:
21663331
[PubMed - indexed for MEDLINE]
16.

Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.

Lewis JH.

Expert Rev Gastroenterol Hepatol. 2010 Feb;4(1):13-29. doi: 10.1586/egh.09.72.

PMID:
20136586
[PubMed - indexed for MEDLINE]
17.

Irritable bowel syndrome.

Spinelli A.

Clin Drug Investig. 2007;27(1):15-33. Review.

PMID:
17177577
[PubMed - indexed for MEDLINE]
18.

Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: a systematic review.

Shi J, Tong Y, Shen JG, Li HX.

World J Gastroenterol. 2008 Jan 21;14(3):454-62. Review.

PMID:
18200670
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.

Schiller LR, Johnson DA.

Am J Gastroenterol. 2008 Apr;103(4):815-9. doi: 10.1111/j.1572-0241.2008.01818.x.

PMID:
18397418
[PubMed - indexed for MEDLINE]
20.

Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work.

Schoenfeld P.

Gastroenterol Clin North Am. 2005 Jun;34(2):319-35, viii. Review.

PMID:
15862938
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk